CytomX Therapeutics, Inc.
CTMX Nasdaq
SEC CIK 1501989
Follow CytomX Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.7M
−71.7% vs same quarter last year
Net income
−$20M
−40.5% vs same quarter last year
EPS, diluted
-
Operating cash flow
$16.6M
+207.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $76.2M | −$17.4M |
| FY24 | $138.1M | $31.9M |
| FY23 | $101.2M | −$569K |
| FY22 | $53.2M | −$99.3M |
| FY21 | $37.3M | −$115.9M |
| FY20 | $68.4M | −$64.8M |
| FY19 | $26.9M | −$132.8M |
| FY18 | $59.5M | −$84.6M |
| FY17 | $71.6M | −$43.1M |
| FY16 | $12.8M | −$58.9M |
| FY15 | $7.7M | −$35.4M |
| FY14 | $5.1M | −$30.3M |
| FY13 | $888K | −$15.1M |
| FY12 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −29.3% | −22.8% |
| FY24 | 18.1% | 23.1% |
| FY23 | −6.4% | −0.6% |
| FY22 | −190.6% | −186.8% |
| FY21 | −311% | −310.5% |
| FY20 | −117.7% | −94.7% |
| FY19 | −525.9% | −493.7% |
| FY18 | −130.9% | −142.2% |
| FY17 | −64.6% | −60.2% |
| FY16 | −463.9% | −458.5% |
| FY15 | −430.5% | −458.7% |
| FY14 | −586.3% | −597% |
| FY13 | −1684.2% | −1705.3% |
| FY12 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$75.8M |
| FY24 | −$86.5M |
| FY23 | −$56.9M |
| FY22 | −$112.5M |
| FY21 | −$120.6M |
| FY20 | $3M |
| FY19 | −$144M |
| FY18 | −$79.3M |
| FY17 | $168.8M |
| FY16 | −$4.2M |
| FY15 | −$29M |
| FY14 | $30.1M |
| FY13 | −$8.7M |
| FY12 | - |
- CytomX Therapeutics
- Healthcare median
Show the numbers
| Year | CytomX Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −22.8% | −30.6% |
| FY24 | 23.1% | −47% |
| FY23 | −0.6% | −58% |
| FY22 | −186.8% | −80.4% |
| FY21 | −310.5% | −71.8% |
| FY20 | −94.7% | −62.2% |
| FY19 | −493.7% | −46.2% |
| FY18 | −142.2% | −49.6% |
| FY17 | −60.2% | −45.9% |
| FY16 | −458.5% | −36% |
| FY15 | −458.7% | −37.8% |
| FY14 | −597% | −35.5% |
| FY13 | −1705.3% | −37.1% |
| FY12 | - | −29.1% |